Medication info
Bialsartan Plus F Tablets

Bialsartan Plus F Tablets

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›25mg / 1 tablet
Manufacturer / importer
Boryung Pharmaceutical Co., Ltd.
Appearance
Yellowish oval film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200802545 · Notified 2008.03.05

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs about 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine only when monotherapy has not produced the expected effect. 1. Replacement therapy: Combination therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows a reduction in the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of a loop diuretic rather than a thiazide-type drug is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment The initial dose of losartan potassium for patients with hepatic impairment who require dose adjustment is 25 mg, which cannot be administered using this medicine. Therefore, use in these patients is not recommended.
Child dose
Under 18 years: There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Boryung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used to treat hypertension that is not adequately controlled by monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs about 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine only when monotherapy has not produced the expected effect. 1. Replacement therapy: Combination therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows a reduction in the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of a loop diuretic rather than a thiazide-type drug is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment The initial dose of losartan potassium for patients with hepatic impairment who require dose adjustment is 25 mg, which cannot be administered using this medicine. Therefore, use in these patients is not recommended.

Child dose

Under 18 years: There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication may pose a significant risk of serious harm or death to the fetus and newborn during pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Patients who have an allergy to this medication or have certain kidney, liver, or electrolyte disorders, pregnant women, and patients with certain genetic lactose intolerance should not take this medication. Patients with hypotension or compromised kidney function, liver disease, hyperuricemia, or gout should be carefully monitored while using this medication. As this medication has blood pressure-lowering effects, dizziness or drowsiness may occur at the beginning of treatment or when the dosage is changed, requiring caution in operating vehicles or machinery. While taking this medication, electrolyte levels in the blood, kidney function, and liver function should be regularly monitored for any abnormalities, particularly paying attention to changes in potassium levels. This medication may interact with other drugs, so patients currently taking other medications must inform their healthcare providers and should not take potassium supplements or potassium-containing salt substitutes without consultation. Photosensitivity reactions may occur due to the hydrochlorothiazide component, so sun exposure should be limited, and if any skin problems develop, immediate consultation with a doctor is necessary. There is no experience using this medication in children and adolescents; therefore, its use in these populations is not recommended. Elderly patients may experience adverse effects more frequently; hence, care should be taken when administering this medication. In the event of an overdose, symptoms such as hypotension and tachycardia may appear, and immediate contact with a medical institution is necessary in emergencies. This medication should be stored in its original container and kept safely out of reach of children.

Side effects

  • Abdominal pain
  • edema
  • palpitations
  • low back pain
  • dizziness
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
Show 125 more
  • skin detachment phenomenon
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • appetite loss
  • constipation
  • toothache
  • dry mouth
  • indigestion
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle stiffness
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory loss
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neurogenic hypersensitivity
  • panic disorder
  • sensory disturbance
  • peripheral neuropathy
  • sleep disorder
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • oropharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • itching
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision loss
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • frequent urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle cramps
  • agitation
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • temporary blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal effusion
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that does not allow light in. Additionally, it is advisable to store it at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness over time.

Appearance and packaging

Appearance

Yellowish oval film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.